Teva Pharmaceutical Indus Q2 2024 Adj. EPS $0.61 Beats $0.55 Estimate, Sales $4.164B Beat $4.056B Estimate
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries reported Q2 2024 adjusted EPS of $0.61, beating the estimate of $0.55. Sales were $4.164 billion, surpassing the expected $4.056 billion.
July 31, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceutical Industries reported better-than-expected Q2 2024 results with an adjusted EPS of $0.61 and sales of $4.164 billion, both surpassing analyst estimates.
Teva's Q2 2024 earnings and sales both exceeded analyst expectations, which is likely to positively impact the stock price in the short term. Beating estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100